Today’s Roddenberry International Symposium on Cellular Reprogramming in San Francisco will be Drs. Shinya Yamanaka and John Gurdon first public appearance together since being named 2012 Nobel Laureates, according to the ISSCR’s (International Society for Stem Cell Research) website. The Roddenberry International Symposium is a collaborative effort between the ISSCR and the Roddenberry Center for Stem Cell Biology and Medicine at the Gladstone Institutes.
The symposium explores the latest research on reprogramming mature cells (such as skin or fat cells) into pluripotent cells -- capable of differentiating into different types of body cells. These reprogrammed cells hold the promise of being applied in medical treatments for therapeutic gain in the future.
More than 25 of the world's top stem cell scientists -- from top global research institutions such as the National Institutes of Health, the California Institute for Regenerative Medicine, the Wellcome Trust Centre for Stem Cell Research, University of Cambridge, UCSF, Stanford, UCLA, MIT Kyoto University and Memorial Sloan-Kettering Cancer Center – have gathered to discuss recent research, advances and perspectives in cellular reprogramming.
Fluidigm Corporation is a gold sponsor of the event and is exhibiting its new C 1™ Single-Cell AutoPrep System, as well as presenting three posters on current and future applications of its integrated fluidic chip technology for single-cell analysis.Fluidigm is a key supplier to the scientific research community investigating stem cell genomic signatures down to the single-cell level. “We are proud to provide many of these institutions with tools that allow researchers to gather genomic information at the single-cell level,” said Gajus Worthington, Fluidigm President and Chief Executive Officer. The conference emphasizes the important role that stem cells will have in advancing life science and medical understanding, ultimately with the goal of enhancing medical practices in the future. The Rodenberry Foundation, sponsor of this symposium, sees this work as a positive, important step in bringing to reality a number of concepts for better health options.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV